Novavax shares rise after Q2 revenue beat, 2026 guidance lift
Novavax says Q2 revenue of $56.7 million topped Wall Street consensus and it raised full-year 2026 revenue guidance to $235 million-$275 million, supporting a late-morning stock gain.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
7 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Ross Stores raises 2026 earnings guidance after Q2 double beat
Ross Stores reported second-quarter revenue of $6.27 billion and earnings of $2.66 per share, both above estimates, and lifted 2026 earnings guidance to $8.61-$8.77 per share.
Moderna, Walmart and Strategy drive retail buzz after news flow
Retail traders focused on Moderna, Walmart, Strategy, Broadcom and SpaceX this week, with Moderna on positive Phase 3 cancer vaccine data, Walmart on fiscal second-quarter results, and Strategy on a stock sale and unchanged Bitcoin holdings.
Iovance Biotherapeutics trades at 52-week high after sector-linked momentum
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is trading at a 52-week high despite no company-specific news, while the post also cites second-quarter results and reaffirmed fiscal 2026 sales guidance.
Treasury buybacks drag yields lower; gold, miners rally
The Treasury’s decision to at least double long-dated debt buybacks pushed benchmark yields lower, weakened the dollar to its lowest since late May and lifted gold-related assets.
Moderna, Merck cancer vaccine hits key Phase 3 endpoints
Moderna and Merck say their personalized mRNA cancer vaccine intismeran with Keytruda met key endpoints in a Phase 3 melanoma trial, cutting recurrence and distant metastasis versus Keytruda alone.
Merck, Moderna report positive phase 3 melanoma results
Merck and Moderna say the phase 3 INTERPATH-001 trial of intismeran autogene plus Keytruda met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in completely resected Stage IIb-IV melanoma.